Share This Author
Xpd/Ercc2 regulates CAK activity and mitotic progression
It is shown that the Drosophila TFIIH component Xpd negatively regulates the cell cycle function of Cdk7, the CAK activity, resulting in decreased Cdk T-loop phosphorylation, mitotic defects and lethality, whereas a decrease in Xpd results in increasedCAK activity and cell proliferation.
The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma.
The E1 enzyme is highlighted as a novel target for the treatment of hematologic malignancies after being evaluated at the level of the ubiquitin-activating enzyme UBA1 (E1) by immunoblotting and a novel small molecule inhibitor is discovered.
The Fused/Smurf Complex Controls the Fate of Drosophila Germline Stem Cells by Generating a Gradient BMP Response
Mutation in TRMU related to transfer RNA modification modulates the phenotypic expression of the deafness-associated mitochondrial 12S ribosomal RNA mutations.
Findings indicate that the mutated TRMU, acting as a modifier factor, modulates the phenotypic manifestation of the deafness-associated 12S rRNA mutations.
Mapping fertility-restoring genes of rice WA cytoplasmic male sterility using SSLP markers
RM244, another SSLP marker on the short arm of chromosome 10, was found to be linked with a fertility restorer locus in an F 2 population consisting of 30 exces- sive sterile individuals from a cross between Zhenshan 97A and a weak restorer line IR64, which gave promise of application in molecular marker-assisted selection for fertility restoredr lines of the CMS-WA system.
Lysosomal disruption preferentially targets acute myeloid leukemia cells and progenitors.
- M. Sukhai, S. Prabha, A. Schimmer
- Biology, ChemistryThe Journal of clinical investigation
- 2 January 2013
It is demonstrated that lysosomal disruption preferentially targets AML cells and AML progenitor cells, providing a rationale for testing lysOSomal disruption as a novel therapeutic strategy for AML.
Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE). Part I: Structure guided discovery and optimization of dual targeting agents with potent, broad-spectrum enzymatic…
Biochemical characterization of the mitochondrial tRNASer(UCN) T7511C mutation associated with nonsyndromic deafness.
- Xiaoming Li, N. Fischel‐Ghodsian, F. Schwartz, Qingfeng Yan, R. Friedman, M. Guan
- BiologyNucleic Acids Research
- 1 February 2004
We report here the biochemical characterization of the deafness-associated mitochondrial tRNA(Ser(UCN)) T7511C mutation, in conjunction with homoplasmic ND1 T3308C and tRNA(Ala) T5655C mutations…
Effect of noncompetitive proteasome inhibition on bortezomib resistance.
- Xiaoming Li, Tabitha E. Wood, A. Schimmer
- BiologyJournal of the National Cancer Institute
- 21 July 2010
5AHQ is a noncompetitive proteasome inhibitor that is cytotoxic to myeloma and leukemia cells in vitro and inhibits xenograft tumor growth in vivo and can overcome some forms of bortezomib resistance in vitro.